InsiderTrades.com logo
Jason Haas net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Jason Haas Biography and Net Worth

CFO of Odyssey Therapeutics

Mr. Haas is a dynamic business leader with over 25 years of experience in healthcare investment banking and the biotechnology industry. Prior to joining Odyssey, he served as Chief Financial Officer at Syros Pharmaceuticals, Inc. Previously, Mr. Haas served as Co-head of Americas, Healthcare Investment Banking at Barclays plc and Head of Americas, Healthcare Investment Banking at Deutsche Bank AG. Before that, he was a Managing Director on the Healthcare Investment Banking team at Goldman Sachs & Co. Mr. Haas currently serves on the board of directors of Ligand Pharmaceuticals Incorporated. Mr. Haas earned his Bachelor of Arts in international relations and economics from Colgate University and his Master of Business Administration in finance from Columbia Business School.

What is Jason Haas' net worth?

The estimated net worth of Jason Haas is at least $114.49 thousand as of August 12th, 2026. Haas owns 3,981 shares of Odyssey Therapeutics stock worth more than $114,494 as of September 6th. This net worth evaluation does not reflect any other assets that Haas may own. Learn More about Jason Haas' net worth.

How do I contact Jason Haas?

The corporate mailing address for Haas and other Odyssey Therapeutics executives is 51 Sleeper Street Suite 800, Boston, MA 02210, US. Odyssey Therapeutics can also be reached via phone at 617-865-9628 and via email at [email protected]. Learn More on Jason Haas' contact information.

Has Jason Haas been buying or selling shares of Odyssey Therapeutics?

Jason Haas has not been actively trading shares of Odyssey Therapeutics during the last ninety days. Most recently, on Friday, May 8th, Jason Haas bought 1,000 shares of Odyssey Therapeutics stock. The stock was acquired at an average cost of $20.00 per share, with a total value of $20,000.00. Following the completion of the transaction, the chief financial officer now directly owns 62,908 shares of the company's stock, valued at $1,258,160. Learn More on Jason Haas' trading history.

Who are Odyssey Therapeutics' active insiders?

Odyssey Therapeutics' insider roster includes Shelley Chu (Director), Jason Haas (CFO), Jeffrey Leiden (Director), and Nan Li (Director). Learn More on Odyssey Therapeutics' active insiders.

Are insiders buying or selling shares of Odyssey Therapeutics?

During the last year, Odyssey Therapeutics insiders bought shares 7 times. They purchased a total of 4,183,777 shares worth more than $75,319,986.00. During the last year, insiders at the sold shares 1 times. They sold a total of 1,780 shares worth more than $32,040.00. The most recent insider tranaction occured on May, 11th when Director Nan Li bought 1,111,111 shares worth more than $19,999,998.00. Learn More about insider trades at Odyssey Therapeutics.

Information on this page was last updated on 5/11/2026.

Jason Haas Insider Trading History at Odyssey Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/8/2026Buy1,000$20.00$20,000.0062,908View SEC Filing Icon  
See Full Table

Jason Haas Buying and Selling Activity at Odyssey Therapeutics

This chart shows Jason Haas's buying and selling at Odyssey Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Odyssey Therapeutics Company Overview

Odyssey Therapeutics Inc. is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc. is based in BOSTON.
Read More

Today's Range

Now: $28.76
Low: $25.71
High: $29.05

50 Day Range

MA: $20.46
Low: $15.56
High: $28.76

2 Week Range

Now: $28.76
Low: $15.10
High: $29.05

Volume

268,971 shs

Average Volume

165,724 shs

Market Capitalization

$1.38 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A